Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zoetis    ZTS

ZOETIS

(ZTS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Zoetis : Announces Authorization of $2 Billion Share Repurchase Program

share with twitter share with LinkedIn share with facebook
12/12/2018 | 04:23pm EDT

Company Also Declares First Quarter 2019 Dividend; Board Approves 30% Payment Increase

Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has authorized a $2 billion multi-year share repurchase program as part of its long-term capital allocation plans. The shares are expected to be repurchased over a multi-year period, and the program can be cancelled at any time. The company’s previous $1.5 billion share repurchase program, which was approved in December 2016, is expected to be completed in the first half of next year.

The Board of Directors also declared a first quarter 2019 dividend of $0.164 per share, an increase of 30% from the quarterly dividend rate paid in 2018. The dividend is to be paid on Friday, March 1, 2019, to holders of record of the company’s common stock on Friday, January 18, 2019.

“As a result of our consistent performance, financial discipline, and the strength of our business model, Zoetis remains well-positioned to generate cash for future growth and value creation opportunities,” said Juan Ramón Alaix, Chief Executive Officer at Zoetis. “This new share repurchase program, along with the dividend increase, is a demonstration of our ongoing commitment to return excess capital to shareholders as part of our capital allocation priorities.”

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets medicines, vaccines, and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, expectations regarding the performance of acquired companies and our ability to integrate new businesses, expectations regarding the financial impact of acquisitions, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.govwww.zoetis.com, or on request from Zoetis.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
All news about ZOETIS
09/15ZOETIS : Named a Top Company for Working Mothers
BU
09/10ZOETIS INC. : Other Events (form 8-K)
AQ
09/10ZOETIS : 09/10/2020 Zoetis to Participate in the 18th Annual Morgan Stanley Heal..
PU
09/10ZOETIS : to Participate in the 18th Annual Morgan Stanley Healthcare Conference
BU
09/09ZOETIS : Launches Vetscan Imagyst™, a New Diagnostic Platform to Detect In..
PU
08/12GLOBAL MARKETS LIVE: Cisco, Orsted, Foxconn…
08/07LIVESTOCK HIGHLIGHTS : Top Stories of the Day
DJ
08/06ZOETIS : Management's Discussion and Analysis of Financial Condition and Results..
AQ
08/06Zoetis 2Q Livestock Products Sales Fall Amid Less Demand From Food-Service Se..
DJ
08/06Zoetis Posts Higher 2Q Profit, Raises Fiscal Year Outlook
DJ
More news
Financials (USD)
Sales 2020 6 421 M - -
Net income 2020 1 583 M - -
Net Debt 2020 3 658 M - -
P/E ratio 2020 48,9x
Yield 2020 0,50%
Capitalization 76 422 M 76 422 M -
EV / Sales 2020 12,5x
EV / Sales 2021 11,5x
Nbr of Employees 10 600
Free-Float 94,6%
Chart ZOETIS
Duration : Period :
Zoetis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZOETIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 170,24 $
Last Close Price 160,84 $
Spread / Highest target 18,8%
Spread / Average Target 5,84%
Spread / Lowest Target -27,3%
EPS Revisions
Managers
NameTitle
Kristin C. Peck Chief Executive Officer & Director
Mike B. McCallister Non-Executive Chairman
Roxanne Lagano Chief Human Resources Officer
Glenn C. David Chief Financial Officer & Executive Vice President
Catherine Ann Knupp Executive VP, President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ZOETIS21.53%76 422
ELANCO ANIMAL HEALTH INCORPORATED-8.83%12 668
JINYU BIO-TECHNOLOGY CO., LTD.43.00%4 419
DECHRA PHARMACEUTICALS PLC10.34%4 390
VIRBAC-19.15%1 872
TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.42.15%1 189